Pharmaceutical Business Review - Clinical Trials News
34 followers 6 articles/week
Santhera’s vamorolone NDA receives priority review in China

Sperogenix Therapeutics, the company’s rare disease partner in China, filed the application with the NMPA. The Center for Drug Evaluation (CDE) of the NMPA accepted the filing after The post Santhera’s vamorolone NDA receives priority review in China appeared first on Pharmaceutical Business review.

Thu Mar 28, 2024 13:47
Cipla enters deal to distribute Sanofi’s CNS products in India

This collaboration is expected to leverage Cipla’s extensive distribution network to enhance the reach of Sanofi India’s CNS products. Under the agreement, Cipla will handle the distribution and The post Cipla enters deal to distribute Sanofi’s CNS products in India appeared first on Pharmaceutical Business review.

Wed Mar 27, 2024 13:41
Q32 Bio concludes merger deal with Homology Medicines

With the deal closing, the merged business will now function under the name Q32 Bio. Concurrent with the merger’s closure, Q32 Bio also finalised a $42m private placement. The post Q32 Bio concludes merger deal with Homology Medicines appeared first on Pharmaceutical Business review.

Tue Mar 26, 2024 13:36
EMA CHMP recommends marketing authorisation for Novartis’ PNH treatment

This endorsement is a significant step towards the availability of Fabhalta for PNH patients in Europe. The positive opinion is based on data from two Phase III clinical The post EMA CHMP recommends marketing authorisation for Novartis’ PNH treatment appeared first on Pharmaceutical Business review.

Mon Mar 25, 2024 13:24
FDA approves Italfarmaco’s Duvyzat for DMD treatment

This development marks the first nonsteroidal medication authorised to treat DMD patients with all genetic variants of a rare neurological disorder. A histone deacetylase (HDAC) inhibitor, Duvyzat can The post FDA approves Italfarmaco’s Duvyzat for DMD treatment appeared first on Pharmaceutical Business review.

Fri Mar 22, 2024 15:39
Evommune expands EVO756 collaboration with Maruho in Asia

EVO756 is a highly selective small molecule antagonist targeting mas-related G-protein coupled receptor X2 (MRGPRX2), a receptor implicated in various inflammatory conditions. This partnership builds on a previous The post Evommune expands EVO756 collaboration with Maruho in Asia appeared first on Pharmaceutical Business review.

Thu Mar 21, 2024 15:24

Build your own newsfeed

Ready to give it a go?
Start a 14-day trial, no credit card required.

Create account